Global Growth Factors Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Growth Factors Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Growth Factors market finds that the global Growth Factors market reached a value of USD 68278.18 million in 2022. It’s expected that the market will achieve USD 85686.6 million by 2028, exhibiting a CAGR of 3.86% during the forecast period.

Drivers

North America region is the largest market of Growth factors, with a revenue market share of 45.54% in 2018. Europe is the second largest market of Growth factor, enjoying revenue market share of 31.75% in
2018. With the economic development, the demand in China and India is increasing.
One of the hottest and most talked about topics in skin treatment is Growth Factors. People's pursuit of beauty drives the development of growth factors in the field of skin treatment.

Region Overview:

From 2023-2028, North America is estimated to witness robust growth prospects.

Company Overview:

Novo Nordisk A/S is one of the major players operating in the Growth Factors market, holding a share of 23.70% in 2019.

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells

Segmentation Overview:

Among different product types, Good Manufacturing Practice (GMP) segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Renal disorders segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Growth Factors market covered in Chapter 3:

Eli Lilly and Company
AbbVie Inc
Amgen Inc
Sanofi
Merck & Co., Inc
Novo Nordisk A/S
Johnson & Johnson
Novartis AG

In Chapter 4 and Chapter 14.2, on the basis of types, the Growth Factors market from 2018 to 2029 is primarily split into:

Good Manufacturing Practice (GMP)
Research Use Only (RUO)

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Growth Factors market from 2018 to 2029 covers:

Anemia
Renal disorders
Cancer
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)